A Phase 1/1b open-label, dose-escalation and dose-expansion trial to evaluate the safety, tolerability, PK, PD, and clinical activity of etrumadenant in participants with triple-negative breast cancer. This trial includes 2 different cohorts: etrumadenant in combination with PLD, or etrumadenant in combination with PLD and IPI-549.
Key Eligibility Criteria
- Participants must have histologically confirmed ER-negative, PgR-negative, and HER2-negative breast cancer that is metastatic, advanced, or recurrent with progression for which no alternative or curative therapy exists
- No history of surgery, or GI dysfunction that may affect drug absorption for participants assigned to the IPI-549 arm(s)